O'Connor Donal 4

What Happened
Donal O'Connor, a director of Theravance Biopharma (TBPH), was granted equity on 2026-06-12. The filing shows an award/acquisition of 6,009 shares at $0.00 and a derivative award of 13,398 shares (also $0.00). No cash was paid for these awards; the total reported acquisition amount is $0.

Key Details

• Transaction date: 2026-06-12; Form 4 filed 2026-06-16 (filed within the SEC’s two-business-day window).
• Grants: 6,009 shares (direct award) and 13,398 derivative shares (award of equity-linked instrument) at $0.00 per share.
• Shares owned after transaction: Not specified in this filing.
• Footnote (F1): The derivative award vests 1/12th per month of service after the grant date, with any remaining unvested shares vesting on the next annual shareholders’ meeting provided the director remains in continuous service.
• Transaction code: A = Award/Grant (derivative indicates an option/RSU-like instrument).

Context
This was an equity grant to a director, not an open-market purchase or sale. Awards at $0.00 are typical for stock-based compensation and are intended to align insider and shareholder interests; they are not direct indications of immediate buying/selling intent. The derivative component carries a monthly vesting schedule with a catch-up vesting at the next annual meeting per the footnote.